Comparative Pharmacology
Head-to-head clinical analysis: CHOLEBRINE versus SCANLUX 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEBRINE versus SCANLUX 370.
CHOLEBRINE vs SCANLUX-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholebrine is an iodinated contrast agent that attenuates X-rays, improving visualization of anatomical structures during imaging procedures.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
1-2 mCi (37-74 MBq) intravenously as a single dose for hepatobiliary scintigraphy.
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 6-12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <5%.
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent